InMed Pharmaceuticals (INM) Cash from Financing Activities (2020 - 2026)

InMed Pharmaceuticals has reported Cash from Financing Activities for 7 years, with the latest figure at $231675.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 92.07% year-over-year to $231675.0; the trailing twelve-month figure through Mar 2026 stood at $8.3 million (up 101.84% YoY), and the FY2025 full-year result was $12.3 million, up 163.66% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $231675.0, up from -$137178.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $8.2 million in Q2 2025, with the low at -$137178.0 in Q3 2025.
• Historically, Cash from Financing Activities has averaged $2.3 million across 5 years, with a median of $588380.0 in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 117.31% — and 2025, when it jumped 4644531.25%.
• InMed Pharmaceuticals' Cash from Financing Activities stood at $5.3 million in 2022, then sank by 101.2% to -$63697.0 in 2023, then soared by 631.46% to $338521.0 in 2024, then tumbled by 140.52% to -$137178.0 in 2025, then surged by 268.89% to $231675.0 in 2026.
• The last three Cash from Financing Activities figures came in at $231675.0 (Q1 2026), -$137178.0 (Q3 2025), and $8.2 million (Q2 2025), per Business Quant data.